Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXIM PHARMACEUTICALS (MMP) -- Ignore unavailable to you. Want to Upgrade?

To: Christopher Ting who wrote (1)	9/28/1997 6:51:00 PM
From: Bashby	Respond to of 10

Christopher: I listened to a tape of the Informed Investors Forum held in San Diego during August. The Maxim presentation was beguiling, but I could find no MMP thread in SI. Since your reply the company has announced a "world wide" underwriting of 2,500,000 common shares. They must surely have told their story in San Diego with full knowledge that their stock deal was ripening. The abrupt rise of the stock probably has more to do with the underwriting than it does with their presentation at the Forum. Underwriters, especially those of OTC deals, frequently seem to have worked with market makers to inflate the market price of a stock prior to an under- writing. I started the MMP thread hoping to find folks out there who would know enough of the technology to give us a fix on the reality and the promise of the MMP research. The U.S. underwriter is new to me: Rodman & Renshaw. The other lead underwriter is an Oslo firm. R&R seems to have done 4 deals this year, of which I have examined only one. That security seems now to be selling at about 1/3 of its issue price earlier this year. I hope, for Maxim's sake, that the other R&R deals worked out better, otherwise we might be better advised to short MMP now and cover after the underwriting. WRE

To: Christopher Ting who wrote (1)	9/28/1997 7:05:00 PM
From: Bashby	Respond to of 10

Christopher: I listened to a tape of the Informed Investors Forum held in San Diego during August. The Maxim presentation was beguiling, but I could find no MMP thread in SI. Since your reply the company has announced a "world wide" underwriting of 2,500,000 common shares. They must surely have told their story in San Diego with full knowledge that their stock deal was ripening. The abrupt rise of the stock probably has more to do with the underwriting than it does with their presentation at the Forum. Underwriters, especially those of OTC deals, frequently seem to have worked with market makers to inflate the market price of a stock prior to an under- writing. I started the MMP thread hoping to find folks out there who would know enough of the technology to give us a fix on the reality and the promise of the MMP research. The U.S. underwriter is new to me: Rodman & Renshaw. The other lead underwriter is an Oslo firm. R&R seems to have done 4 deals this year, of which I have examined only one. That security seems now to be selling at about 1/3 of its issue price earlier this year. I hope, for Maxim's sake, that the other R&R deals worked out better, otherwise we might be better advised to short MMP now and cover after the underwriting when more shares will be available and the price may be softer. WRE

To: Christopher Ting who wrote (1)	2/7/1999 2:56:00 PM
From: THE LEPRECHAUN	Read Replies (1) \| Respond to of 10

Is anyone taking notice of this stock as phase III trial results in june and then it will go before the FDA!!!!!!!!! Iwatch the stock price everyday and buy more and more as soon as it drops below 12 3/4. i must be insane or there is something extremely smelly about this one or hopefully no one really understands the potential of a revitalised immunotherapy drug market which still has sales of over $2BLN!!!!!!!! Wake up and smell those histamines and phagocytes!!! Still only two brokers covering this stock as the larger ones have always thought of partnerships. BUT THINGS A CHANGING OK!!!!!! WAKEY WAKEY!!!!!